Transitional Cell Carcinoma Completed Phase 1 Trials for Pembrolizumab (DB09037)

Also known as: Carcinoma, Transitional Cell / Carcinoma transitional cell / Transitional cell carcinoma (morphologic abnormality)

IndicationStatusPhase
DBCOND0031000 (Transitional Cell Carcinoma)Completed1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02443324A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract CancerTreatment